『AI and DTB, drug safety, tirzepatide, and lecanemab for Alzheimer's disease』のカバーアート

AI and DTB, drug safety, tirzepatide, and lecanemab for Alzheimer's disease

AI and DTB, drug safety, tirzepatide, and lecanemab for Alzheimer's disease

無料で聴く

ポッドキャストの詳細を見る

このコンテンツについて

 In this podcast accompanying the August issue of DTB (https://dtb.bmj.com/content/63/8), David Phizackerley (DTB Editor) is joined by James Cave (former DTB Editor-in-Chief). David and James discuss an editorial generated by artificial intelligence (AI) (https://dtb.bmj.com/content/63/8/114) which looks at the role of AI in publishing. They talk about a DTB Forum article (https://dtb.bmj.com/content/63/8/115) that explores some of the practical problems of implementing drug safety alerts. A DTB Select article (https://dtb.bmj.com/content/63/8/117) provides an overview of a double-blind, randomised, placebo-controlled trial of tirzepatide for weight reduction in people without diabetes. They finish by reviewing the main article (https://dtb.bmj.com/content/63/8/118) that provides an overview of the evidence for lecanemab for the treatment of mild cognitive impairment and mild dementia due to Alzheimer’s disease. Link BMJ policy on AI use: https://www.bmj.com/content/ai-use
まだレビューはありません